Literature DB >> 20024586

Severe respiratory adverse events associated with rituximab infusion.

Koichi Kamei, Shuichi Ito, Kazumoto Iijima.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20024586     DOI： 10.1007/s00467-009-1408-2

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


× No keyword cloud information.
  2 in total

1.  Fatal pulmonary fibrosis after rituximab administration.

Authors:  Marie-Camille Chaumais; Arnaud Garnier; François Chalard; Michel Peuchmaur; Stephane Dauger; Evelyne Jacqz-Agrain; Georges Deschênes
Journal:  Pediatr Nephrol       Date:  2009-04-25       Impact factor: 3.714

Review 2.  Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature.

Authors:  Martin Bitzan; Mark Anselmo; Lucy Carpineta
Journal:  Pediatr Pulmonol       Date:  2009-09
  2 in total
  12 in total

1.  Rituximab for refractory cases of childhood nephrotic syndrome.

Authors:  Jameela A Kari; Salah M El-Morshedy; Sherif El-Desoky; Hammad O Alshaya; Khawla A Rahim; Burhan M Edrees
Journal:  Pediatr Nephrol       Date:  2011-01-31       Impact factor: 3.714

Review 2.  Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children.

Authors:  Koichi Kamei; Kenji Ishikura; Mayumi Sako; Shuichi Ito; Kandai Nozu; Kazumoto Iijima
Journal:  Pediatr Nephrol       Date:  2018-12-18       Impact factor: 3.714

Review 3.  New therapies, new concerns: rituximab-associated lung injury.

Authors:  Larry C Lands
Journal:  Pediatr Nephrol       Date:  2010-03-02       Impact factor: 3.714

4.  Drug-Free Macromolecular Therapeutics Induce Apoptosis via Calcium Influx and Mitochondrial Signaling Pathway.

Authors:  Lian Li; Jiyuan Yang; Jiawei Wang; Jindřich Kopeček
Journal:  Macromol Biosci       Date:  2017-08-14       Impact factor: 4.979

5.  Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis.

Authors:  Juhi Kumar; Ibrahim F Shatat; Amy L Skversky; Robert P Woroniecki; Marcela Del Rio; Eduardo M Perelstein; Valerie L Johnson; Shefali Mahesh
Journal:  Pediatr Nephrol       Date:  2012-10-04       Impact factor: 3.714

6.  Should we consider MMF therapy after rituximab for nephrotic syndrome?

Authors:  Guido Filler; Shih-Han Susan Huang; Ajay P Sharma
Journal:  Pediatr Nephrol       Date:  2011-05-01       Impact factor: 3.714

7.  Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome.

Authors:  Anne-Laure Sellier-Leclerc; Emre Belli; Valérie Guérin; Peter Dorfmüller; Georges Deschênes
Journal:  Pediatr Nephrol       Date:  2013-05-23       Impact factor: 3.714

8.  Cell surface self-assembly of hybrid nanoconjugates via oligonucleotide hybridization induces apoptosis.

Authors:  Te-Wei Chu; Jiyuan Yang; Rui Zhang; Monika Sima; Jindřich Kopeček
Journal:  ACS Nano       Date:  2013-12-10       Impact factor: 15.881

9.  Anti-CD20 multivalent HPMA copolymer-Fab' conjugates for the direct induction of apoptosis.

Authors:  Te-Wei Chu; Jiyuan Yang; Jindřich Kopeček
Journal:  Biomaterials       Date:  2012-07-12       Impact factor: 12.479

10.  Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.

Authors:  Shuichi Ito; Koichi Kamei; Masao Ogura; Tomohiro Udagawa; Shuichiro Fujinaga; Mari Saito; Mayumi Sako; Kazumoto Iijima
Journal:  Pediatr Nephrol       Date:  2012-10-10       Impact factor: 3.651
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.